156 related articles for article (PubMed ID: 30952881)
21. In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease.
Schemmert S; Camargo LC; Honold D; Gering I; Kutzsche J; Willuweit A; Willbold D
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207233
[TBL] [Abstract][Full Text] [Related]
22. Amyloid aggregation inhibitory mechanism of arginine-rich D-peptides.
Olubiyi OO; Frenzel D; Bartnik D; Glück JM; Brener O; Nagel-Steger L; Funke SA; Willbold D; Strodel B
Curr Med Chem; 2014; 21(12):1448-57. PubMed ID: 24304283
[TBL] [Abstract][Full Text] [Related]
23. d-Enantiomeric RTHLVFFARK-NH
Liu W; Dong X; Sun Y
ACS Chem Neurosci; 2019 Mar; 10(3):1390-1401. PubMed ID: 30650306
[TBL] [Abstract][Full Text] [Related]
24. The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway.
Chang YJ; Chen YR
FEBS J; 2014 Jun; 281(11):2674-87. PubMed ID: 24720730
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of amyloid Aβ aggregation by high pressures or specific d-enantiomeric peptides.
Cavini IA; Munte CE; Erlach MB; van Groen T; Kadish I; Zhang T; Ziehm T; Nagel-Steger L; Kutzsche J; Kremer W; Willbold D; Kalbitzer HR
Chem Commun (Camb); 2018 Mar; 54(26):3294-3297. PubMed ID: 29537428
[TBL] [Abstract][Full Text] [Related]
26. MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.
Rammes G; Gravius A; Ruitenberg M; Wegener N; Chambon C; Sroka-Saidi K; Jeggo R; Staniaszek L; Spanswick D; O'Hare E; Palmer P; Kim EM; Bywalez W; Egger V; Parsons CG
Neuropharmacology; 2015 May; 92():170-82. PubMed ID: 25637092
[TBL] [Abstract][Full Text] [Related]
27. QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Brener O; Dunkelmann T; Gremer L; van Groen T; Mirecka EA; Kadish I; Willuweit A; Kutzsche J; Jürgens D; Rudolph S; Tusche M; Bongen P; Pietruszka J; Oesterhelt F; Langen KJ; Demuth HU; Janssen A; Hoyer W; Funke SA; Nagel-Steger L; Willbold D
Sci Rep; 2015 Sep; 5():13222. PubMed ID: 26394756
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
[TBL] [Abstract][Full Text] [Related]
30. Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.
Alemi M; Silva SC; Santana I; Cardoso I
CNS Neurosci Ther; 2017 Jul; 23(7):605-619. PubMed ID: 28570028
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.
Jiang N; Leithold LH; Post J; Ziehm T; Mauler J; Gremer L; Cremer M; Schartmann E; Shah NJ; Kutzsche J; Langen KJ; Breitkreutz J; Willbold D; Willuweit A
PLoS One; 2015; 10(6):e0128553. PubMed ID: 26046986
[TBL] [Abstract][Full Text] [Related]
32. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.
Ma QL; Lim GP; Harris-White ME; Yang F; Ambegaokar SS; Ubeda OJ; Glabe CG; Teter B; Frautschy SA; Cole GM
J Neurosci Res; 2006 Feb; 83(3):374-84. PubMed ID: 16385556
[TBL] [Abstract][Full Text] [Related]
33. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.
Teng E; Taylor K; Bilousova T; Weiland D; Pham T; Zuo X; Yang F; Chen PP; Glabe CG; Takacs A; Hoffman DR; Frautschy SA; Cole GM
Neurobiol Dis; 2015 Oct; 82():552-560. PubMed ID: 26369878
[TBL] [Abstract][Full Text] [Related]
34. The new β amyloid-derived peptide Aβ1-6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity.
Diomede L; Romeo M; Cagnotto A; Rossi A; Beeg M; Stravalaci M; Tagliavini F; Di Fede G; Gobbi M; Salmona M
Neurobiol Dis; 2016 Apr; 88():75-84. PubMed ID: 26792398
[TBL] [Abstract][Full Text] [Related]
35. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
[TBL] [Abstract][Full Text] [Related]
36. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
Kreutzer AG; Nowick JS
Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
[TBL] [Abstract][Full Text] [Related]
37. Amyloid-β Peptide Nitrotyrosination Stabilizes Oligomers and Enhances NMDAR-Mediated Toxicity.
Guivernau B; Bonet J; Valls-Comamala V; Bosch-Morató M; Godoy JA; Inestrosa NC; Perálvarez-Marín A; Fernández-Busquets X; Andreu D; Oliva B; Muñoz FJ
J Neurosci; 2016 Nov; 36(46):11693-11703. PubMed ID: 27852777
[TBL] [Abstract][Full Text] [Related]
38. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
Schartmann E; Schemmert S; Ziehm T; Leithold LHE; Jiang N; Tusche M; Joni Shah N; Langen KJ; Kutzsche J; Willbold D; Willuweit A
Eur J Pharm Sci; 2018 Mar; 114():93-102. PubMed ID: 29225107
[TBL] [Abstract][Full Text] [Related]
39. α-Sheet secondary structure in amyloid β-peptide drives aggregation and toxicity in Alzheimer's disease.
Shea D; Hsu CC; Bi TM; Paranjapye N; Childers MC; Cochran J; Tomberlin CP; Wang L; Paris D; Zonderman J; Varani G; Link CD; Mullan M; Daggett V
Proc Natl Acad Sci U S A; 2019 Apr; 116(18):8895-8900. PubMed ID: 31004062
[TBL] [Abstract][Full Text] [Related]
40. Quantification and targeting of elusive neurotoxic amyloid oligomers.
Bhatt N; Kayed R
Cell Rep Med; 2022 May; 3(5):100636. PubMed ID: 35584632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
